Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations

Modern Pathology

Volumn 29, Issue 6, 2016, Pages 570-581

  Siddiqi, Imran N ^a   Friedman, Julia ^b   Barry Holson, Keegan Q ^a   Ma, Charles ^b   Thodima, Venkata ^b   Kang, Irene ^a   Padmanabhan, Raghavendra ^b   Dias, Lizalynn M ^b   Kelly, Kevin R ^a   Brynes, Russell K ^a   Kamalakaran, Sitharthan ^b   Houldsworth, Jane ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CANCER GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD23 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HERPESVIRUS ENTRY MEDIATOR; INTERLEUKIN 4; JANUS KINASE; KI 67 ANTIGEN; PHOSPHOPROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; STAT6 PROTEIN; VINCRISTINE; BCL2 PROTEIN, HUMAN; IMMUNOGLOBULIN E RECEPTOR; STAT6 PROTEIN, HUMAN; TNFRSF14 PROTEIN, HUMAN; TUMOR MARKER;

1P36 GENE; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOLOGY; DIFFUSE NODAL FOLLICULAR LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE; GENE DELETION; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRAIT; GENETIC VARIABILITY; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; INGUINAL LYMPH NODE; MALE; MIDDLE AGED; PRIORITY JOURNAL; T LYMPHOCYTE; VERY ELDERLY; CHEMISTRY; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME DELETION; CHROMOSOME DISORDER; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGY; MUTATION; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROCEDURES;

ADULT; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, IGE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; STAT6 TRANSCRIPTION FACTOR; TRANSLOCATION, GENETIC;

EID: 84960448170     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.51     Document Type: Article

References (32)

1. Harris NL, Nathwani BN, Swerdlow SH, et al. Follicular lymphoma In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4th edn. IARC: Lyon, France, 2008, pp 220-226.
2. Jaffe ES. Follicular lymphomas: a tapestry of common and contrasting threads. Haematologica. 2013; 98: 1163-1165.
3. Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14; 18)-negative nodal follicular non- Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009; 113: 1053-1061.
4. Thorns C, Kalies K, Fischer U, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology. 2007; 50: 716-719.
5. Olteanu H, Fenske TS, Harrington AM, et al. CD23 expression in follicular lymphoma: clinicopathologic correlations. Am J Clin Pathol. 2011; 135: 46-53.
6. Bouska A, McKeithan TW, Deffenbacher KE, et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 2014; 123: 1681-1690.
7. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011; 476: 298-303.
8. Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013; 122: 3165-3168.
9. Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015; 125: 658-667.
10. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014; 6: 130-140.
11. Li H, Kaminski MS, Li Y, et al. Mutations in linker histone genes HIST1H1 B C D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 2014; 123: 1487-1498.
12. Dias LM, Thodima V, Friedman J, et al. Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015; 21: 1-27.
13. Houldsworth J, Guttapalli A, Thodima V, et al. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 55: 920-928.
14. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma interNational prognostic index. Blood. 2004; 104: 1258-1265.
15. Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014; 46: 176-181.
16. Yildiz M, Li H, Bernard D, et al. Activating STAT6 mutations in follicular lymphoma. Blood. 2015; 125: 668-679.
17. Wang E, West D, Kulbacki E. An unusual nodal marginal zone lymphoma with bright CD10 expression: a potential diagnostic pitfall. Am J Hematol. 2010; 85: 546-548.
18. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13: 140-147.
19. Dave BJ, Hess MM, Pickering DL, et al. Rearrangements of chromosome band 1p36 in non-Hodgkin's lymphoma. Clin Cancer Res. 1999; 5: 1401-1409.
20. Martin-Guerrero I, Salaverria I, Burkhardt B, et al. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica. 2013; 98: 1237-1241.
21. Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012; 26: 559-562.
22. Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010; 70: 9166-9174.
23. Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009; 113: 137-148.
24. Cheung KJ, Delaney A, Ben-Neriah S, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010; 49: 669-681.
25. Viardot A, Möller P, Högel J, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol. 2002; 20: 4523-4530.
26. Schwaenen C, Viardot A, Berger H, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer. 2009; 48: 39-54.
27. Braggio E, Dogan A, Keats JJ, et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012; 25: 651-660.
28. Krijgsman O, Gonzalez P, Ponz OB, et al. Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features. Haematologica. 2013; 98: 1921-1929.
29. Neelapu SS. Mutations and microenvironment collude in FL. Blood. 2015; 125: 587-589.
30. Pangault C, Amé-Thomas P, Ruminy P, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010; 24: 2080-2089.
31. Kneitz C, Goller M, Seggewiss R, et al. STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia. Leuk Res. 2000; 24: 331-337.
32. Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood. 2008; 112: 1424-1433.